I believe Vascepa's sales force are concentrating
On high volume clinics in only large metropolitan areas. Amarin has been overburdened with the very expensive cost of the R-it trial and without the financial help from the Anchor label which was part of the original understanding between the FDA and Amarin. Amarin has always keep its agreements with the FDA to date. The FDA, an agency of our gov't, unfortunately has failed to meet most of their obligations with Amarin. Sorry to say, it is business as usual for this administration. So unfortunately, expenses being what they are, Amarin is forced to market to areas that provide the most impact, so yes many doctors have not heard of Vascepa. Personally, I like this little company and their management, because they have managed to exist through the most trying of times, and have managed to win several court victories to boot. The interim results should validate and disprove the reasoning of the FDA cancelling the Anchor label. I believe this company has the fight in it to succeed. AMO. GLTAL's.